Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) EBT Margin (2016 - 2023)

Historic EBT Margin for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to 3280.68%.

  • RedHill Biopharma's EBT Margin rose 32446700.0% to 3280.68% in Q2 2023 from the same period last year, while for Jun 2023 it was 111.91%, marking a year-over-year increase of 378200.0%. This contributed to the annual value of 181.69% for FY2024, which is 5479300.0% down from last year.
  • Latest data reveals that RedHill Biopharma reported EBT Margin of 3280.68% as of Q2 2023, which was up 32446700.0% from 220.03% recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBT Margin registered a high of 3280.68% during Q2 2023, and its lowest value of 658.08% during Q4 2021.
  • Over the past 5 years, RedHill Biopharma's median EBT Margin value was 67.81% (recorded in 2020), while the average stood at 368.88%.
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -14921500bps in 2021, then soared by 32446700bps in 2023.
  • Over the past 5 years, RedHill Biopharma's EBT Margin (Quarter) stood at 744.47% in 2019, then plummeted by -91bps to 70.29% in 2020, then plummeted by -1036bps to 658.08% in 2021, then increased by 17bps to 543.22% in 2022, then surged by 704bps to 3280.68% in 2023.
  • Its EBT Margin was 3280.68% in Q2 2023, compared to 220.03% in Q1 2023 and 543.22% in Q4 2022.